The most common adverse events reported with both treatments were mild to moderate gastrointestinal-related side effects.

Adults on the obesity medication tirzepatide (Zepbound) lost more weight on average than those on semaglutide (Wegovy) in a ...

Tirzepatide showed superior weight loss efficacy over semaglutide in a phase 3b trial, achieving primary and secondary endpoints. Tirzepatide is the only FDA-approved dual GIP and GLP-1 receptor ...

Patients lost an average of 20.2% of their weight with tirzepatide over 72 weeks versus 13.7% with semaglutide.

New data suggests that the benefits of Novo Nordisk’s GLP-1 agonist semaglutide in preventing cardiovascular diseases may not simply be a result of weight loss. The analysis comes from long-term ...

When it comes to planning pregnancy while using weight loss medications, timing is everything. Medical professionals urge ...

137 million of all adults in the United States are candidates for semaglutide with the majority for weight loss and diabetes. This comprises 26.8 million Medicare, 13.8 million Medicaid as well as ...

They also slow down the movement of food through the stomach and curb appetite, thereby causing weight loss. Semaglutide (GLP-1) weight-loss drug Wegovy, made by pharmaceutical company Novo ...

Novo Nordisk, the manufacturer of Ozempic and Wegovy, has petitioned the Food and Drug Administration (FDA) to add ...

Findings showed tirzepatide was superior to semaglutide for both the primary endpoint and all key secondary endpoints at 72 weeks. Average weight loss in the tirzepatide group was 20.2% compared ...